Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease.
Dopamine metabolism genes
Dyskinesia
MAO-B polymorphism
Parkinson's disease
Journal
eNeurologicalSci
ISSN: 2405-6502
Titre abrégé: eNeurologicalSci
Pays: Netherlands
ID NLM: 101667077
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
12
02
2019
revised:
31
03
2020
accepted:
02
04
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
30
4
2020
Statut:
epublish
Résumé
Dopamine replacement therapy is an established treatment for motor symptoms of Parkinson's disease, but its long-term use is often limited by the eventual development of motor complications, including levodopa-induced dyskinesia. Genetic background, particularly polymorphisms of dopamine metabolism genes, may affect the occurrence of dyskinesia in Parkinson's disease patients. We investigated polymorphisms of dopamine metabolism genes, including catechol- Monoamine oxidase B rs1799836 was the only polymorphism correlated with risk of dyskinesia. Patients with an AG or GG genotype were more likely to have dyskinesia than those with an AA genotype (adjusted hazard ratio, 3.41; 95% confidence interval, 1.28-9.10). Also, Kaplan-Meier curves demonstrated that patients with an AG or GG genotype developed dyskinesia earlier than those with an AA genotype (log-rank test, In Parkinson's disease patients, the monoamine oxidase B rs1799836 G allele is associated with a greater likelihood of developing dyskinesia than the A allele, possibly due to its association with lower monoamine oxidase B activity in the brain. Thus, detection of monoamine oxidase B polymorphisms may be useful for determining the optimal dosing of antiparkinson medications.
Sections du résumé
BACKGROUND
BACKGROUND
Dopamine replacement therapy is an established treatment for motor symptoms of Parkinson's disease, but its long-term use is often limited by the eventual development of motor complications, including levodopa-induced dyskinesia. Genetic background, particularly polymorphisms of dopamine metabolism genes, may affect the occurrence of dyskinesia in Parkinson's disease patients.
METHODS
METHODS
We investigated polymorphisms of dopamine metabolism genes, including catechol-
RESULTS
RESULTS
Monoamine oxidase B rs1799836 was the only polymorphism correlated with risk of dyskinesia. Patients with an AG or GG genotype were more likely to have dyskinesia than those with an AA genotype (adjusted hazard ratio, 3.41; 95% confidence interval, 1.28-9.10). Also, Kaplan-Meier curves demonstrated that patients with an AG or GG genotype developed dyskinesia earlier than those with an AA genotype (log-rank test,
CONCLUSIONS
CONCLUSIONS
In Parkinson's disease patients, the monoamine oxidase B rs1799836 G allele is associated with a greater likelihood of developing dyskinesia than the A allele, possibly due to its association with lower monoamine oxidase B activity in the brain. Thus, detection of monoamine oxidase B polymorphisms may be useful for determining the optimal dosing of antiparkinson medications.
Identifiants
pubmed: 32346620
doi: 10.1016/j.ensci.2020.100239
pii: S2405-6502(20)30018-6
pii: 100239
pmc: PMC7183157
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100239Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
None.
Références
Pharmacogenomics J. 2001;1(2):152-6
pubmed: 11911442
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Neuropsychobiology. 2003;48(4):190-3
pubmed: 14673217
Nat Rev Genet. 2006 Apr;7(4):306-18
pubmed: 16543934
Lancet Neurol. 2010 Nov;9(11):1106-17
pubmed: 20880751
PLoS One. 2014 May 16;9(5):e93772
pubmed: 24834916
Am J Hum Genet. 2001 Feb;68(2):515-22
pubmed: 11170900
PLoS One. 2013;8(1):e54108
pubmed: 23365649
Brain. 2004 Dec;127(Pt 12):2747-54
pubmed: 15329355
Mov Disord. 2008 Apr 30;23(6):837-44
pubmed: 18307261
Mol Psychiatry. 1997 Jan;2(1):44-56
pubmed: 9154217
Hum Genet. 2002 Jan;110(1):1-7
pubmed: 11810289
Psychiatry Res. 1998 Nov 16;81(2):117-23
pubmed: 9858029
Mov Disord. 2012 Jan;27(1):132-5
pubmed: 22083803
Nat Rev Neurosci. 2008 Sep;9(9):665-77
pubmed: 18714325
Nat Neurosci. 2005 May;8(5):594-6
pubmed: 15821730
Mol Psychiatry. 1999 May;4(3):290-6
pubmed: 10395223
J Hum Genet. 2012 Dec;57(12):807-8
pubmed: 22992774
Parkinsonism Relat Disord. 2014 Oct;20(10):1041-5
pubmed: 25034874
Genet Test Mol Biomarkers. 2012 May;16(5):406-11
pubmed: 22283331
Nat Rev Neurosci. 2006 Apr;7(4):295-309
pubmed: 16552415
Ann Neurol. 1995 Mar;37(3):403-5
pubmed: 7695241
BMC Neurol. 2011 Jul 25;11:89
pubmed: 21781348
Neurology. 2003 Jun 10;60(11):1750-5
pubmed: 12796525
Am J Med Genet. 1997 Apr 18;74(2):154-6
pubmed: 9129714
Neurosci Lett. 2002 Dec 16;334(3):206-10
pubmed: 12453630
Brain. 2014 Oct;137(Pt 10):2731-42
pubmed: 25034897
J Clin Pharmacol. 2018 Jul;58(7):920-926
pubmed: 29578580
Neurology. 2001 Oct 23;57(8):1497-9
pubmed: 11673599
Mov Disord. 2013 Jul;28(8):1064-71
pubmed: 23630119